Obesity drugmaker Novo Nordisk posts strong profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted on Wednesday (Nov ...
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted on Wednesday (Nov ...
ASTRAZENECA’S market value surged above £200 billion (S$338 billion) for the first time after a big bet on cancer drugs ...
Citi estimates Zantac settlement costs at US$3 billionGSK shares plunged in the wake of a court ruling that the UK ...
Japan’s Asahi Kasei said on Tuesday (May 28) it offered to acquire Calliditas Therapeutics for about US$1.1 billion as part ...
Indian drugmaker Abbott India reported a 24 per cent rise in fourth-quarter profit on Thursday (May 9), as strong sales ...
Japan’s Takeda Pharmaceutical said full-year earnings slumped by more than half as the company focused on rebuilding its drug pipeline ...
Danish pharmaceutical giant Novo Nordisk reported more soaring profits on Thursday (May 2) thanks to the popularity of anti-diabetes and ...
ELI Lilly kicked off construction of a new plant to boost the production of its wildly popular weight-loss drugs, which ...
A CHINESE drugmaker has developed a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic and applied for its approval. Hangzhou ...
A DRUGMAKER in China has developed a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic and applied for approval ...
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2024 Forbes 40under40. All Rights Reserved.